David Kirn, President and Chief Executive Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), filed a Form 4 on September 16, 2026, disclosing the sale of 58,333 shares of common stock on September 14, 2026.

Key Highlights

  • Shares sold: 58,333 shares of common stock disposed of on September 14, 2026
  • Weighted average sale price: $13.903 per share, with individual trades ranging from $13.43 to $14.15, inclusive
  • Remaining ownership: 767,486 shares of common stock held directly following the transaction
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Kirn on January 9, 2026
  • Reporting person role: David Kirn is identified as both a Director and Officer (President and Chief Executive Officer)

David Kirn's September 2026 Share Disposition at 4D Molecular Therapeutics

According to the filing, David Kirn, who serves as President and Chief Executive Officer and as a Director of 4D Molecular Therapeutics, Inc., disposed of 58,333 shares of the company's common stock on September 14, 2026. The transaction was executed under transaction code "S," indicating a sale. The Form 4 was signed by Scott Bizily as Attorney-in-Fact for David Kirn and filed on September 16, 2026.

The filing discloses that the sale was executed in multiple trades at prices ranging from $13.43 to $14.15, inclusive. The weighted average sale price reported is $13.903 per share. According to the filing, Kirn "undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote." Following the transaction, Kirn directly holds 767,486 shares of common stock.

The filing notes that the transaction was made pursuant to a 10b5-1 trading plan adopted by Kirn on January 9, 2026. The form indicates that a box was checked to reflect that the transaction was "made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)." No derivative securities transactions were reported in this filing.

What Was Disclosed

The Form 4 reports a single sale of 58,333 shares of 4D Molecular Therapeutics common stock by CEO David Kirn on September 14, 2026, at a weighted average price of $13.903, under a pre-established 10b5-1 plan, leaving him with 767,486 shares directly held.